- Trials with a EudraCT protocol (82)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
82 result(s) found for: Neurocognitive disorders.
Displaying page 1 of 5.
EudraCT Number: 2020-002196-35 | Sponsor Protocol Number: 73520 | Start Date*: 2020-11-16 |
Sponsor Name:Amsterdam UMC, location VUmc | ||
Full Title: post-trial access cohort BUmetanide for Developmental DIsorders | ||
Medical condition: Neurodevelopmental disorders Autism spectrum disorder Attention deficit hyperactivity disorder (ADHD) Learning disorders | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-003419-12 | Sponsor Protocol Number: SWEAR-1 | Start Date*: 2015-06-18 |
Sponsor Name:AZIENDA OSPEDALIERA SAN GERARDO, MONZA, ITALIA | ||
Full Title: A Pilot Randomized Controlled Trial of Switch to tenofovir disoproxil fumarate/emtricitabine/rilpivirine (TDF/FTC/RPV) versus continue TDF/FTC/efavirenz (EFV) treatment among virologically suppress... | ||
Medical condition: HIV INFECTION | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002810-11 | Sponsor Protocol Number: R727-CL-1609 | Start Date*: 2018-11-19 | |||||||||||||||||||||||||||||||
Sponsor Name:Regeneron Pharmaceuticals, Inc. | |||||||||||||||||||||||||||||||||
Full Title: Long Term Safety Study of PRALUENT in Patients with Heterozygous Familial Hypercholesterolemia or with Non-Familial Hypercholesterolemia at High and Very High Cardiovascular Risk and Previously Enr... | |||||||||||||||||||||||||||||||||
Medical condition: Heterozygous Familial Hypercholesterolemia or Non-Familial Hypercholesterolemia at High and Very High Cardiovascular Risk | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: EE (Prematurely Ended) BG (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-002979-34 | Sponsor Protocol Number: LTFU-ABO-102 | Start Date*: 2020-05-18 | |||||||||||
Sponsor Name:Abeona Therapeutics Inc | |||||||||||||
Full Title: A Long-term Follow-up Study of Patients with MPS IIIA from Gene Therapy Clinical Trials Involving the Administration of ABO-102 (scAAV9.U1a.hSGSH) | |||||||||||||
Medical condition: MPS IIIA is a devastating lysosomal storage disease, caused by a Nsulfoglucosamine sulfohydrolase gene defect. Infants with MPS IIIA appear normal at birth, but the disease is relentlessly progress... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001968-35 | Sponsor Protocol Number: SPIROTREAT | Start Date*: 2015-03-11 | |||||||||||
Sponsor Name:Klinikum der Universität München - AöR vertreten durch den Vorstand des Bereiches umanmedizinH | |||||||||||||
Full Title: Add-on spironolactone for the treatment of schizophrenia | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001818-14 | Sponsor Protocol Number: RELATE-TRD | Start Date*: 2013-12-20 | |||||||||||
Sponsor Name:University Medical Center Groningen | |||||||||||||
Full Title: RELATE and PREDICT TRD A pharmacological and neuroimaging study investigating neurobiological effects of Selective Serotonin Reuptake Inhibitors and Norepinephrine Reuptake inhibitors on dopaminer... | |||||||||||||
Medical condition: Major Depressive Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003601-66 | Sponsor Protocol Number: CSEG101ANL01T | Start Date*: 2021-07-14 | |||||||||||
Sponsor Name:Amsterdam UMC - AMC | |||||||||||||
Full Title: The Effect of Crizanlizumab on Cerebral Perfusion and Oxygenation in Sickle Cell Patients | |||||||||||||
Medical condition: Sickle Cell Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002936-97 | Sponsor Protocol Number: LTFU-ABO-101 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Abeona Therapeutics Europe SL. | |||||||||||||
Full Title: A Long-term Follow-up Study of Patients with MPS IIIB from Gene Therapy Clinical Trials Involving the Administration of ABO-101 (rAAV9.CMV.hNAGLU) | |||||||||||||
Medical condition: MPS IIIB is a devastating lysosomal storage disease, caused by a N-α-acetylglucosaminidase (NAGLU) gene defect. Infants with MPS IIIB appear normal at birth, but the disease is relentlessly progres... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-004425-42 | Sponsor Protocol Number: CHDR0723 | Start Date*: 2008-09-15 | |||||||||||
Sponsor Name:Centre for Human Drug Research | |||||||||||||
Full Title: Neurocognitive testing in children with ADHD | |||||||||||||
Medical condition: Attention Deficit Hyperactivity Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023264-40 | Sponsor Protocol Number: SNC | Start Date*: 2010-10-21 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA S. GERARDO DI MONZA | |||||||||||||
Full Title: Efficacy in the central nervous system (CNS) of two combination regimens with different penetration rank in HIV-positive na�ve patients | |||||||||||||
Medical condition: HIV infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004831-35 | Sponsor Protocol Number: TACT | Start Date*: 2018-04-09 |
Sponsor Name:Dept of Psychiatry, Umeå University Hospital | ||
Full Title: TACT –Thiamine in Anorexia Clinical Trial | ||
Medical condition: Patients with Anorexia Nervosa and Healthy Controls | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-003558-98 | Sponsor Protocol Number: CHDR1939 | Start Date*: 2020-02-10 |
Sponsor Name:Centre for Human Drug Research | ||
Full Title: Randomized, double-blind, placebo-controlled, two way crossover, single centre study evaluating the acute and chronic effect of clonazepam on cognitive tests and patient-reported outcome measures i... | ||
Medical condition: ARID1B-related intellectual disability | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-003741-29 | Sponsor Protocol Number: MARAND-X | Start Date*: 2017-04-05 | ||||||||||||||||
Sponsor Name:A.S.L. TO 2 | ||||||||||||||||||
Full Title: MARAND-X Study: MARaviroc-based Treatment Switch in HIV-positive Patients with HAND: Consequences of Reducing Antiretroviral-associated NeurotoXicity | ||||||||||||||||||
Medical condition: HIV-infection, HIV-associated neurocognitive disorders | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005581-37 | Sponsor Protocol Number: 5946 | Start Date*: 2012-08-06 | |||||||||||
Sponsor Name:The Newcastle upon Tyne Hospitals NHS Foundation Trust | |||||||||||||
Full Title: Efficacy of Switch to Lopinavir/Ritonavir in Improving Cognitive function in Efavirenz treated patients | |||||||||||||
Medical condition: Cognitive function and sleep pattern in HIV-1 patients | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005908-18 | Sponsor Protocol Number: 1111_1111 | Start Date*: 2021-11-03 | |||||||||||||||||||||
Sponsor Name:AOU FEDERICO II | |||||||||||||||||||||||
Full Title: Functional-genetic stratification as a guide to personalized treatment in developmental and epileptic encephalopathies due to potassium channel mutations | |||||||||||||||||||||||
Medical condition: Epileptic Encephalopathy with developmental delay | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003189-16 | Sponsor Protocol Number: R727-CL-1532 | Start Date*: 2016-12-22 | |||||||||||||||||||||||||||||||
Sponsor Name:Regeneron Pharmaceuticals, Inc. | |||||||||||||||||||||||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Praluent on Neurocognitive Function in Patients with Heterozygous Familial Hypercholesterolemia or with Non-Familial H... | |||||||||||||||||||||||||||||||||
Medical condition: Heterozygous Familial Hypercholesterolemia or Non-Familial Hypercholesterolemia with High and Very High Cardiovascular Risk | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: EE (Completed) BG (Completed) SK (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-001560-35 | Sponsor Protocol Number: 2358 | Start Date*: 2016-04-07 |
Sponsor Name:Brain Center Rudolf Magnus, University Medical Center Utrecht, Department of Psychiatry, Utrecht , the Netherlands | ||
Full Title: Bumetanide in Autism Medication and BIomarker study | ||
Medical condition: Autism Spectrum Disorder | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002740-82 | Sponsor Protocol Number: 1346-0038 | Start Date*: 2019-03-07 | |||||||||||
Sponsor Name:Boehringer Ingelheim Limited | |||||||||||||
Full Title: A phase II randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily with adjunctive Computerized Cognitive Training over 12 wee... | |||||||||||||
Medical condition: schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001322-54 | Sponsor Protocol Number: CS/2018/6632 | Start Date*: 2020-06-15 | ||||||||||||||||||||||||||
Sponsor Name:University Hospitals Bristol and Weston NHS Foundation Trust | ||||||||||||||||||||||||||||
Full Title: Carbon Dioxide Insufflation and Brain Protection During Open Heart Surgery: A Randomised Controlled Trial | ||||||||||||||||||||||||||||
Medical condition: Brain injury during open heart valve surgery | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003772-39 | Sponsor Protocol Number: DEMAND-pilot | Start Date*: 2019-12-13 |
Sponsor Name:Umeå University | ||
Full Title: Diet, physical exercise, and metabolic control intervention to reduce the incidence of major neurocognitive disorders among individuals with type 2 diabetes combined with mild neurocognitive impair... | ||
Medical condition: Type 2 diabetes | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
